Bausch & Lomb Corp (BLCO) Stock Price & Analysis
Bausch & Lomb Corp (BLCO) rose 3.10% to USD 15.65 as of June 10, 2026 at 00:44 UTC, according to Nexqual real-time market data.
BLCO last closed at USD 15.18; the session ranged USD 15.42–15.77 on volume of 398,298 shares. Market capitalization is $5.58B, with a 52-week range of USD 11.44–18.92 (NYQ). Source: Nexqual, June 10, 2026 at 00:44 UTC.
Key Statistics (as of June 10, 2026 at 00:44 UTC)
| Price | USD 15.65 |
|---|---|
| Change | ▲ 3.10% (up) |
| Previous Close | USD 15.18 |
| Open | USD 15.35 |
| Day Range | USD 15.42 – 15.77 |
| 52-Week Range | USD 11.44 – 18.92 |
| Volume | 398,298 shares |
| Market Cap | $5.58B |
| Exchange | NYQ |
Technical Analysis (BLCO)
Nexqual's technical model rates BLCO "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 00:44 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 49.03 (neutral) |
| vs SMA50 | Below (USD 16.01) |
| MACD | -0.22 (negative) |
Analyst Ratings (BLCO)
Wall Street analysts rate BLCO "Buy" based on 12 analysts, with a mean price target of USD 17.88 (range USD 16–21), per Nexqual as of June 10, 2026 at 00:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 17.88 |
| High Target | USD 21 |
| Low Target | USD 16 |
| Buy / Hold / Sell | 5 / 7 / 1 |
Earnings (BLCO)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 0.16 |
| Revenue Estimate | $1.37B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.08 vs est 0.05 ▲ beat |
| 2025-12-31 | USD 0.32 vs est 0.36 ▼ miss |
| 2025-09-30 | USD 0.18 vs est 0.16 ▲ beat |
| 2025-06-30 | USD 0.07 vs est 0.08 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
Financials & Fundamentals (BLCO)
| Total Revenue | $5.21B |
|---|---|
| Revenue Growth (YoY) | +9.40% |
| Gross Margin | +60.62% |
| Operating Margin | +4.74% |
| Profit Margin | -4.21% |
| ROE | -3.28% |
| Debt / Equity | 78.58 |
| Current Ratio | 1.53 |
| Total Cash | $268.00M |
| Total Debt | $5.07B |
| Free Cash Flow | $238.50M |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
Financial Health Score (BLCO)
Nexqual rates Bausch & Lomb Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:44 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 61%, operating 5% |
| Balance Sheet | Mixed — $268M cash vs $5.07B debt |
| Cash Flow | Mixed — FCF $239M, slim 4.7% margin |
| Efficiency | Critical — ROE -3%, ROA 1.4% |
Ownership (BLCO)
| Insider Ownership | +87.36% |
|---|---|
| Institutional Ownership | +11.01% |
| Shares Outstanding | 356.54M |
| Float | 44.91M |
| Short % of Float | +9.03% |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
Leadership (BLCO)
Bausch & Lomb Corp is led by Brenton L. Saunders (age 55), CEO & Chairman, per Nexqual as of June 10, 2026 at 00:44 UTC.
| CEO & Chairman | Brenton L. Saunders (age 55) |
|---|---|
| Executive VP & CFO | Osama A. Eldessouky (age 53) |
| President of Global Pharmaceuticals & International Consumer | Andrew J. Stewart (age 49) |
Major Backers & Investors (BLCO)
Notable institutional backers of Bausch & Lomb Corp include Icahn Carl C, Oaktree Capital Management LP, Shaw D.E. & Co., Inc., according to Nexqual as of June 10, 2026 at 00:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Icahn Carl C | 0.98% |
| Oaktree Capital Management LP | 0.95% |
| Shaw D.E. & Co., Inc. | 0.88% |
| Goldentree Asset Management LP | 0.75% |
| Silver Point Capital L.p. | 0.63% |
| Davidson Kempner Capital Management LP | 0.62% |
| CASPIAN CAPITAL, LP | 0.56% |
| Glenview Capital Management, Llc | 0.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Deutsche Bank AG | 0.99% |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
From Bausch & Lomb Corp's Latest SEC 10-K Filing (filed 2026-02-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally.
- It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.
- The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing.
- It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 5.17 | ▼ 3.72% |
| STVN | Stevanato Group S.p.A. | USD 18.1 | ▼ 1.95% |
| SHC | Sotera Health Company | USD 16.53 | ▲ 5.83% |
| ALC | Alcon Inc. | USD 67.9 | ▲ 1.63% |
| PRVA | Privia Health Group, Inc. | USD 22.17 | ▲ 2.5% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:44 UTC. This page is informational and not investment advice.